In Alzheimer's disease mouse model, HT chronic treatment (10 mg/day by gavage for 14 days) attenuated the spatio-cognitive deficits and normalized the hippocampal BDNF mRNA levels [91]. The gene discussed is BDNF; the disease is early-onset autosomal dominant Alzheimer disease.